World Health Organization evaluates between 200 and 300 million, the number of people who are visually impaired by diseases against which pharmaceutical treatments are however existing. Many of these conditions have in common to cause permanent vision loss if they are not treated consistently.

The lack of adherence to prescription eye drops is the #1 Unmet Medical need in Ophthalmology. Poor treatment Compliance and Adhesion leads to a worse progression of Eye Diseases. BIOPHTA wants to change the lives of patients suffering from chronic eye diseases by creating a best-in-class solution to reduce the burden of treatments.

We develop a new way of treating the eye, with a novel pharmaceutical platform enabling a continuous Drug Delivery.

Our topical Mucoadhesive Ocular Hydrogel Insert releases drugs on the eye for a one-week period, causing higher efficacy & potency for medications. These Ocular Inserts will help patients to improve their adherence to treatment regimens. It also permits a better yield of the drugs by diminishing the frequency and complexity of eye drops application while generating a continuous and controlled sustained release.

BIOPHTA non-invasive topical ocular inserts are aimed at several ophthalmic indications by allowing better long-term control of diseases.

BIOPHTA

🚀 Exciting News! 🚀

BIOPHTA has successfully closed a €6.5 million Seed round to advance our revolutionary technology for treating eye diseases to clinical stage. This significant milestone was made possible with the support of top European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Merieux Equity Partners), Elaia, GO CAPITAL, with participation from one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.

Our first program targets Glaucoma (Phase 1 in 2025), addressing a market valued at $8.7 billion, while our second program focuses on Macular Edema (Phase 1 in 2026), a $9.6 billion market. With these programs, BIOPHTA aims to combat the two leading causes of blindness.

Thank you to our investors and partners for believing in our vision. Together, we are on the path to transforming eye disease treatment! 🌟

Special thanks to Alexandre Boulay, Valérie Calenda, Florian Denis, Valentin T. Fleury and Nathalie Masson.

#Biotech #Investment #Innovation #Ophthalmology #EyeHealth #BIOPHTA #VCFunding #Glaucoma #MacularEdema 
Read the full press release: 
https://lnkd.in/eDUdhgDX

📢 BIOPHTA will be attending the 2024 BIO international convention next week (June3-6) 

👉Book a meeting now 📆 with Jean GARREC in San Diego and join us on our mission to fight blindness 👁



#BIOUS #biotech #ophthalmology #glaucoma #biotechnology #retina #glaucoma #drugdelivery

📢 Join our team and take part in BIOPHTA’s cause to fight blindness ! 👁 

👨‍🔬 We are looking for a 𝐧𝐨𝐧-𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐫 to support our development program ⚗ 

For more information, please apply here :
👉 https://lnkd.in/eEuyteGW

📢 Join our team and take part in BIOPHTA’s cause to fight blindness ! 👁

👨‍🔬 We are looking for a 𝐂𝐌𝐂 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐫 to support our development program ⚗

For more information, please apply here :
👉 https://lnkd.in/ejNFjx3S

📢 Join our team and take part in BIOPHTA’s cause to fight blindness ! 👁

👨‍🔬 We are looking for an 𝐚𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐦𝐚𝐧𝐚𝐠𝐞𝐫 to support our development program ⚗

For more information, please apply here :
👉 https://lnkd.in/eTe8c8G8

BioPhtha is a company that specializes in the development and commercialization of sustainable and eco-friendly chemical products derived from biomass. Their focus is on creating alternatives to petroleum-based chemicals, contributing to a more sustainable chemical industry.

COM:BIOPHTA

BioPhtha

Filings Not Available